risvutatug rezetecan   Click here for help

GtoPdb Ligand ID: 14693

Synonyms: GSK'227 | GSK5764227 | HS-20093 | Ris-Rez
Compound class: Antibody
Comment: Risvutatug rezetecan (GSK5764227, formerly HS-20093; Ris-Rez) is an antibody-drug congugate that targets a camptothecin derived topoisomerase I inhibitor to (tumour) cells expressing CD276 (B7-H3) [2-3,5]. Peptide sequences for risvutatug's heavy and light chains are claimed in Hansoh patent US10899837B2, and these form the antibody named h1702 therein [4].
Click here for help
Bioactivity Comments
Binding affinity data is provided for the parent antibody risvutatug (antibody h1702) as claimed in Hansoh patent US10899837B2 [4]. h1702 binds more potently to the long isoform of human B7-H3, compared to the short isoform and to mouse B7-H3.
Selectivity at other protein targets
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
B7-H3 (CD276) Hs Antibody Binding 6.1 – 8.1 pKd - 4
⤷ pKd 8.1 (Kd 8.6x10-9 M) [4]
Description: Binding affinity determined by BIACore, for the long form (4Ig-B7-H3) of human B7-H3
pKd 6.1 (Kd 7.97x10-7 M) [4]
Description: Binding affinity determined by BIACore, for the short form (2Ig-B7-H3) of human B7-H3
B7-H3 (CD276) Mm Antibody Binding 5.8 pKd - 4
⤷ pKd 5.8 (Kd 1.47x10-6 M) [4]
Description: Binding affinity determined by BIACore, for mouse B7-H3